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doi:10.1016/j.jtcvs.2008.05.018Objective: Although sleeve lobectomy for lung cancer is widely accepted as an alter-
native to pneumonectomy, its use remains controversial. This study aimed to evaluate
the surgical results after sleeve lung resection and to compare the outcomes of differ-
ent procedural approaches.
Methods: The medical records of 201 patients who underwent sleeve lung resection
for lung cancer were retrospectively reviewed. Three groups were compared: a stan-
dard group (lobectomy or bilobectomy; n 5 173), limited group (segmentectomy;
n5 8), and extended group (lobectomy or bilobectomy plus segmentectomy; n5 20).
Results: Three patients died postoperatively (1.4%). Anastomotic complications
occurred in 7 patients (3.4%; fistula in 4 patients, stenosis in 3 patients), 6 of
whom were successfully treated surgically or conservatively. Five-year overall and
disease-free survivals were 57.8% and 50.3%, respectively. Sites of recurrence
included anastomotic sites (n 5 5), ipsilateral thorax (n 5 11), mediastinum (n 5
10), and distant sites (n 5 43). Multivariate analysis showed that the influence of
nodal status on both overall and disease-free survival was significant. All patients
in the limited group but 1 who underwent lobectomy for recurrence in another lobe
are alive without recurrence. Three patients in the extended group experienced distant
metastasis, but none experienced local recurrences. Multivariate analysis showed
extended group-to-standard group hazard ratios of 0.53 (95% confidence interval,
0.23–1.23) for overall survival and 0.48 (95 confidence interval, 0.22–1.05) for
disease-free survival.
Conclusion: Sleeve lung resection can achieve local tumor control and long-term sur-
vival with low mortality and few anastomotic complications. Nodal status signifi-
cantly affects long-term survival. Limited and extended resections are also feasible
with local and long-term results comparable to those of standard sleeve lobectomy.
A
lthough sleeve lobectomy for primary lung cancer was initially used to avoid
pneumonectomy in patients with impaired pulmonary function, recent stud-
ies suggest that it is the alternative of choice to pneumonectomy even for
patients with sufficient pulmonary reserve.1-5
However, the indications for sleeve lobectomy or pneumonectomy are still contro-
versial and depend on each surgeon. In fact, bronchoplastic procedures are performed
in 3% to 19% patients who undergo lung resection for primary lung cancer.2,3,6-8
We used bronchoplastic procedures when technically and oncologically possible to
preserve lung parenchyma in patients with primary lung cancer, avoid pneumonec-
tomy in patients with locally advanced tumor, and avoid lobectomy in patients with
early endobronchial tumor.
The purpose of this study is to describe our single-institution experience of sleeve
lung resection for primary lung cancer and to assess the surgical results of 3
approaches: standard (lobectomy or bilobectomy), limited (segmentectomy), and
extended (lobectomy or bilobectomy plus segmentectomy).The Journal of Thoracic and Cardiovascular Surgery c Volume 136, Number 5 1349
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CI 5 confidence interval
Materials and Methods
Of 2296 patients who underwent operation for primary lung cancer
between 1986 and 2006 in our institution, the National Hospital
Organization, Himeji Medical Center, 201 (8.7%) underwent
sleeve lung resection. The medical records of these patients were
reviewed retrospectively. Those who underwent carinal resection
orwedge resection of the bronchuswere excluded. The datawere col-
lected from hospital charts, referring physicians, and the patients or
the patients’ family. The protocol of this retrospective study was ap-
proved by the institutional ethics committee of the National Hospital
Organization, Himeji Medical Center. Individual consent of patients
was waived because individual patients are not identified.
Sleeve lung resection was always applied to preserve as much
lung parenchyma as possible when the tumor and involved lymph
nodes could be completely resected by the technique. Three types
of sleeve lung resection were performed for maximum preservation
of lung parenchyma: sleeve lobectomy or bilobectomy as a standard
procedure for central tumors located at the origin of a lobar bronchus
(standard group), sleeve segmentectomy for early endobronchial
tumor at the origin of a segmental bronchus to avoid lobectomy
(limited group), and sleeve lobectomy or bilobectomy plus segmen-
tectomy for a locally advanced tumor that could not be resected by
standard sleeve lobectomy or bilobectomy (extended group).
Standard surgical technique was used for lobectomy and seg-
mentectomy until the bronchus was encountered.Mediastinal lymph
node dissection was routinely performed before the bronchus was
cut to avoid further dissection around the bronchus after completion
of the bronchial anastomosis. Circumferential bronchial resection
was performed to create a sufficient margin around the tumor bed.
Frozen sections of the resected margins were examined to ensure
complete resection. Anastomosis was performed with interrupted
sutures using 3-0 Vicryl (Ethicon, Somerville, NJ) in end-to-end
fashion or telescope fashion. All the knots were tied outside the
bronchus. Concomitant wedge or sleeve resection of the pulmonary
artery was performed when necessary using 5-0 Prolene (Ethicon).
Pedicled intercostal muscle flap or pericardial fat tissue was not
routinely used.
Patients were extubated in the operating room or intensive care
unit after the procedure. In addition to standard postoperative man-
agement for conventional lung resection, bronchofiberscopy to clear
bronchial secretion was aggressively performed when necessary.
Bronchofiberscopy was routinely performed 3 to 4 weeks after the
operation to observe the condition of the anastomosis. After dis-
charge, bronchofiberscopy was planned when stenosis or recurrence
at the anastomotic site was suspected.
Resection was considered complete when the resection margins
were free of disease. Pathologic staging was performed according to
the New International Staging System for Lung Cancer.9
For follow-up, patients were observed from the date of the oper-
ation to the time of death or March of 2007. Operative mortality was
defined as death within 30 days after the operation or in-hospital
death without discharge. The site of recurrence was classified as
anastomotic, within the ipsilateral thorax, mediastinal, or distant.1350 The Journal of Thoracic and Cardiovascular Surgery c NThe cause of death was classified as local recurrence, distant metas-
tasis, second primary lung cancer, other cause, or unknown. Sur-
vival was calculated, and adverse events including all-cause death
were evaluated.
Survivals were calculated by life-table analysis. Kaplan–Meier
curves were plotted and compared using the log-rank test for univar-
iate analysis. The results of the multivariate analysis of independent
prognostic factors and type of procedure were assessed using the
Cox proportional hazards model with backward selection.
Results
Patient Characteristics
A total of 201 patients (187 male and 14 female; mean age,
66.8 6 8.3 years [range, 28–82 years]) underwent sleeve
lung resection for primary lung cancer during the 21-year pe-
riod of the study. The mean follow-up period was 50 months
(range, 0–189 months).
Twenty-two patients received preoperative induction ther-
apy. Twenty patients received 1 to 2 cycles of chemotherapy.
One patient received concurrent chemoradiotherapy (2 cycles
of chemotherapy plus 40 Gy of radiotherapy), and 1 patient
received 20 Gy of radiotherapy preoperatively.
Histology identified 163 squamous cell carcinomas
(81%), 26 adenocarcinomas (12%), 2 adenosquamous cell
carcinomas (0.9%), and 10 non-adeno, nonsquamous cell
carcinomas (3 large cell carcinomas, 3 carcinoids, 2 small
cell carcinomas, 1 adenoid cystic carcinoma, and 1 other).
Fifty-four patients (26%) had T1 disease, 108 patients
(53%) had T2 disease, 27 patients (13%) had T3 disease,
and 11 patients (5%) had T4 disease. A total of 103 patients
(51%) had N0 disease, 56 patients (27%) had N1 disease, and
42 patients (20%) had N2 disease. Resection was incomplete
in 11 patients (5.4%) who also had a positive bronchial
margin.
Type of Resection
Table 1 shows the type of procedure and concomitant vascu-
lar resection. Standard procedures (sleeve lobectomy or bilo-
bectomy) were performed in 173 patients (standard group),
limited procedures (sleeve segmentectomy) were performed
in 8 patients (limited group), and extended procedures (sleeve
lobectomy or bilobectomy plus segmentectomy) were per-
formed in 20 patients (extended group). Concomitant sleeve
or wedge resection of the pulmonary artery for invasion of the
tumor was performed in 49 patients (sleeve in 33 patients,
wedge in 16 patients).
Operative Morbidity and Mortality
Table 2 shows the operative morbidity and mortality. A total
of 105 complications occurred in 80 patients (39%). In this
series, 51 patients had prolonged air leak more than 7 days,
but only 2 of these patients required re-thoracotomy. Anasto-
motic complications occurred in 7 patients (fistula in 4
patients, stenosis in 3 patients). All 4 patients withovember 2008
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TSTABLE 1. Types of resection
Vascular resection
Type of procedure Sleeve Wedge
Standard group 173
Right
Upper lobe 70 4 7
Middle lobe 1
Lower lobe 9
Upper-middle lobe 8 2
Middle-lower lobe 22 1
Left
Upper lobe 49 16 7
Lower lobe 14 1 2
Limited group 8
Right
Middle lobe, S6 2
S6 1
Left
Lingula 1
Upper division of upper lobe 3
S6 1
Extended group 20
Right
Upper lobe, S6 3 1
Upper-middle lobe, S6 2 1
Left
Upper lobe, S6 8 7
Lingula, lower lobe 7
Total 201 33 16
TABLE 2. Postoperative complications
Complications Morbidity (%) Mortality
Bronchial complications
Anastomotic fistula 4 (1.9)
Anastomotic stenosis 3 (1.4)
Pulmonary complications
Empyema 6 (2.9)
Pneumonia 6 (2.9)
Respiratory failure 2 (0.9) 1
Interstitial pneumonia 2 (0.9)
Prolonged air leak $ 7 d 51 (25)
Atelectasis requiring
bronchoscopy
12 (5.9)
Cardiovascular complications
Arrhythmia 4 (1.9)
Embolism of popliteal artery 1
Other complications
Postoperative bleeding
requiring re-thoracotomy
6 (2.9) 1
Chylothorax 6 (2.9)
Horner's syndrome 1 (0.4)
Recurrent nerve palsy 1 (0.4)
Other in-hospital death 1
Total 105 (80 patients) 3The Journal of Thoraanastomotic fistula were treated surgically. One of these 4 pa-
tients who had empyema caused by fistula was treated by
omentopexy. The other 3 patients without empyema were
successfully treated surgically (pedicled muscle flap in 2
patients, completion pneumonectomy in 1 patient). Three
patients experienced late anastomotic stenosis. The general
condition of 1 patient was too poor to warrant further inter-
vention, and only tracheostomy was performed to control
bronchial secretion. This patient died of recurrence 30
months after surgery. The second patient underwent re-anas-
tomosis successfully, and the third patient was successfully
treated by balloon dilatation.
Three patients died postoperatively (1.4%). One patient
died on the nineteenth postoperative day from respiratory
failure after the surgical procedure. Preoperative pulmonary
function of this patient was low (forced expiratory volume
in 1 second: 840 mL) and was considered an absolute contra-
indication to pneumonectomy. One patient died on the thirty-
eighth postoperative day from metastasis to the adrenal
gland. One patient died on the third postoperative day from
intrathoracic bleeding after wedge resection of the pulmonary
artery.
Survival
Follow-up was completed in 194 patients (96%). Overall
5- and 10-year survivals were 57.8% and 44.5%, respec-
tively. Disease-free survivals were 50.3% and 42.5%, respec-
tively. Tables 3 and 4 list prognostic factors investigated in
this study. Significant prognostic factors in univariate analy-
sis and type of procedure were entered into multivariate anal-
ysis, which identified nodal status as the only significant
prognostic factor for both overall and disease-free survivals.
Overall 5- and 10-year survivals were 72.6% and 60.3% in
patients with N0 disease, 48.9% and 35.3% in patients with
N1 disease, and 32.9% and 19.2% in patients with N2 dis-
ease, respectively (Figure 1). Disease-free 5- and 10-year sur-
vivals were 69.6% and 60.3% in patients with N0 disease,
37.6% and 28.2% in patients with N1 disease, and 20.6%
and 20.6% in patients with N2 disease, respectively
(Figure 2).
Sites of Recurrence and Cause of Death
Of the 91 patients who died, death was due to lung cancer re-
currence in 53 (local in 15 patients and distant in 38 patients)
and second primary lung cancer in 3. Of the 11 patients with
positive bronchial margin, 6 died of lung cancer recurrence,
which was at the anastomotic site in 2 of these cases.
If the data are limited to 5 years follow-up to avoid bias
by the difference of follow-up period, 76 patients died and
death was due to lung cancer recurrence in 49 patients (local
in 15 patients and distant in 34 patients) and second primary
cancer in 2 patients. Of 21 patients who died of other cause,
6 had recurrence. The first sites of recurrence for the entirecic and Cardiovascular Surgery c Volume 136, Number 5 1351
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TSTABLE 3. Univariate and multivariate analyses for overall survival
Univariate analysis Multivariate analysis
Risk factor n P value P value HR 95% CI
Gender Male/female 187/14 NS
Age, y ,70/more 116/85 NS
Symptoms No/Yes 57/144 NS
Smoking No/Yes 11/190 NS
FEV1 $70/less 122/79 NS
Neoadjuvant therapy No/Yes 179/22 NS
Side Right/Left 118/83 NS
Type of procedure Standard/Limited/Extended 173/8/20 NS .1
Standard/Limited 173/8 NS .2 0.32 0.04–2.34
Standard/Extended 173/20 NS .1 0.53 0.23–1.23
Angioplasty No/Yes 152/49 NS
Histology Squamous/Adenocarcinoma/Others 163/26/12 NS NS
Squamous/Adenocarcinoma 163/26 .04 NS
Invaded stump No/Yes 190/11 .01 NS
T T1/T2/T3/T4 54/108/27/11 .03 .04 1.31 1.00–1.71
N N0/N1/N2 103/56/42 .0000 .000 1.77 1.35–2.31
M M0/M1 198/3 .0001 .02 5.22 1.20–22.61
FEV1, Forced expiratory volume in 1 second; HR, hazard ratio; CI, confidence interval; NS, not significant.group included anastomotic sites (n 5 5), ipsilateral thorax
(n 5 11), mediastinum (n 5 10), and distant sites (n 5 43).
Analysis According to Type of Procedure
Limited group (n 5 8). Table 5 summarizes the patient
characteristics, surgical procedures, pathologic findings, and
prognosis of the limited group (7 men and 1 woman; mean
age, 64 years [range, 28–78 years]). Overall follow-up ranged1352 The Journal of Thoracic and Cardiovascular Surgery c Nofrom 13 to 127 months, with a mean of 47 months. The histo-
logic cell type was squamous cell carcinoma in 6 patients and
carcinoid in 2 patients. Complete resection was performed in
all patients. Nodal stage wasN0 in 5 patients, N1 in 2 patients,
and N2 in 1 patient. There was no postoperative death, and
only 1 patient developed prolonged air leak postoperatively.
Only 1 patient experienced local recurrence in the ipsilateral
lobe (right upper lobe), which was successfully resectedTABLE 4. Univariate and multivariate analyses for disease-free survival
Univariate analysis Multivariate analysis
Risk factor n P value P value HR 95% CI
Gender Male/Female 187/14 NS
Age ,70/more 116/85 NS
Symptoms No/Yes 57/144 NS
Smoking No/Yes 11/190 NS
FEV1 $70/less 122/79 NS
Neoadjuvant therapy No/Yes 179/22 .004 .03 1.84 1.05–3.21
Side Right/Left 118/83 .03 NS
Type of procedure Standard/Limited/Extended 173/8/20 NS .06
Standard/Limited 173/8 NS .1 0.22 0.03–1.63
Standard/Extended 173/20 NS .06 0.48 0.22–1.05
Angioplasty No/Yes 152/49 NS
Histology Squamous/Adenocarcinoma/Others 163/26/12 .0009 NS
Squamous/Adenocarcinoma 163/26 .0003 NS
Invaded stump No/Yes 190/11 .02 .02 2.27 1.09–4.75
T T1/T2/T3/T4 54/108/27/11 .005 NS
N N0/N1/N2 103/56/42 .0000 .000 1.90 1.49–2.42
M M0/M1 198/3 .02 NS
FEV1, Forced expiratory volume in 1 second; HR, hazard ratio; CI, confidence interval; NS, not significant.vember 2008
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TSsurgically. This patient died of another cause 35 months after
the operation. Overall 5-year survival of this group was 83%.
Extended group (n5 20). Table 6 summarizes the patient
characteristics, surgical procedures, pathologic findings, and
prognosis of the extended group (20 men; mean age, 65 years
[range, 49–78 years]). Overall follow-up ranged from 13 to
113 months, with a mean of 50 months. The histologic cell
type was squamous cell carcinoma in 16 patients, adenocar-
cinoma in 3 patients, and large cell carcinoma in 1 patient.
Complete resection was performed in 18 patients. Concomi-
tant sleeve resection of the pulmonary artery was carried out
in 9 patients. Nodal stage was N0 in 7 patients, N1 in 9
patients, and N2 in 4 patients.
There was no postoperative death. Two patients (numbers
8 and 17) had postoperative pneumonia and empyema. Pa-
tient number 8 experienced postoperative pneumonia fol-
lowed by empyema without fistula, which was successfully
treated conservatively. Patient number 17 experienced empy-
ema caused by necrosis of the remaining right upper lobe.
This patient underwent completion sleeve pneumonectomy
and open thoracotomy. Omentopexy was used to close the
open thoracotomy, and this patient is free from recurrence
33 months after the operation.
Overall and disease-free 5-year survivals were 67% and
65%, respectively. Three patients experienced distant metas-
Figure 1. Life-table graph of overall survival according to nodal
status. Overall 5- and 10-year survivals were 72.6% and 60.3% in
patients with N0 disease, 48.9% and 35.3% in patients with N1 dis-
ease, and 32.9% and 19.2% in patients with N2 disease, respec-
tively.The Journal of Thoratasis, but no local recurrences have occurred. Multivariate
analysis showed extended group-to-standard group hazard
ratios of 0.53 (95% confidence interval [CI], 0.23–1.23) for
overall survival and 0.48 (95 CI, 0.22–1.05) for disease-
free survival.
Discussion
Currently, sleeve lobectomy is widely accepted as an altera-
tive to pneumonectomy for centrally located lung tumors in
patients with uncompromised lung function.1-5 Recent stud-
ies suggest that pneumonectomy compared with sleeve lo-
bectomy may not increase survival, and therefore sleeve
lobectomy has become the procedure of choice even in pa-
tients with N2 disease.1,8 However, each surgeon decides
what the indications are for sleeve lobectomy or pneumonec-
tomy. In fact, bronchoplastic procedures have been per-
formed in 3% to 19% of patients who underwent lung
resection for primary lung cancer.2,3,6-8 This is partly because
sleeve resections are technically demanding, and there is still
a fear of local recurrence.
We have used bronchoplastic procedures to preserve as
much lung parenchyma as possible and avoid pneumonec-
tomy and lobectomy. Okada and colleagues1,6,10 reported
that in addition to standard sleeve lobectomy, aggressive
Figure 2. Life-table graph of disease-free survival according to
nodal status. Disease-free 5- and 10-year survivals were 69.6%
and 60.3% in patients with N0 disease, 37.6% and 28.2% in patients
with N1 disease, and 20.6% and 20.6% in patients with N2 disease,
respectively.cic and Cardiovascular Surgery c Volume 136, Number 5 1353
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TSTABLE 5. Characteristics of extended group
No. Sex Age Resected lung
PA
resection Histology T N M Complication Recurrence Prognosis Cause of death
1 M 73 Left UL S6 Sleeve LA x 1 0 No No 91 mo, alive
2 M 66 Right UL S6 SQ 2 2 0 Prolonged air leak Distant 18 mo, dead Diastasis
metastasis
3 M 75 Left UL S6 Sleeve SQ 1 0 0 Prolonged air leak No 61 mo, alive
4 M 78 Right UL S6 SQ 2 2 0 Atelectasis No 67 mo, alive
5 M 66 Left UL S6 Sleeve SQ 2 0 0 Prolonged air leak No 61 mo, alive
6 M 68 Left UL S6 Sleeve SQ 4 1 0 Prolonged air leak No 85 mo, alive
7 M 67 Left LL S415 SQ 2 1 0 No No 113 mo, alive
8 M 68 Right UL S6 AD 1 1 0 Atelectasis, pneumonia,
empyema
No 69 mo, dead Other cause
9 M 49 Left LL S415 SQ 1 0 0 No No 72 mo, alive
10 M 64 Left LL S415 SQ 2 1 0 No Distant 49 mo, dead Diastasis
metastasis
11 M 76 Left LL S415 SQ 3 1 0 No No 49 mo, dead Other cause
12 M 51 Left LL S415 SQ 2 2 0 No No 47 mo, alive
13 M 65 Left UL S6 SQ 2 0 0 No No 13 mo, dead Other cause
14 M 61 Left LL S415 AD 2 0 0 No No 44 mo, alive
15 M 59 Right UL ML S6 Sleeve AD 2 1 0 Prolonged air leak Distant 42 mo, alive
16 M 59 Left UL S6 Sleeve SQ 2 2 0 Prolonged air leak No 38 mo, alive
17 M 57 Right UL ML S6 Sleeve SQ 3 1 0 Pneumonia, empyema No 33 mo, alive
18 M 70 Left LL S415 SQ 2 0 0 No No 21 mo, dead Other cause
19 M 67 Left UL S6 Sleeve SQ 3 0 0 No No 15 mo, alive
20 M 73 Left UL S6 Sleeve SQ 2 1 0 No No 14 mo, alive
PA, Pulmonary artery; UL, upper lobe; LL, lower lobe, ML, middle lobe; LA, large cell carcinoma; SQ, squamous cell carcinoma, AD, adenocarcinoma.application of bronchoplastic procedures to avoid pneumo-
nectomy (extended sleeve lobectomy) and sleeve segmentec-
tomy to avoid lobectomy are feasible with good local control
and long-term survival. Thus, if bronchoplastic procedures
offer good surgical results or at least results equal to those
of standard pneumonectomy and lobectomy, the consequent
increase in preserved lung parenchyma could contribute to
a better quality of life and retain the possibility of resection
of a second primary lung cancer.
One of the greatest concerns for bronchoplastic proce-
dures is its association with relatively high mortality and
morbidity. In a recent meta-analysis, Ferguson and col-1354 The Journal of Thoracic and Cardiovascular Surgery c Nleagues4 reported a mean operative mortality of 4.1% (CI,
2.3%–5.9%) due to sleeve lobectomy and 6.0% (CI, 1%–
11%) due to pneumonectomy. In our series, 3 patients died
postoperatively (1.4%): One death was due to systemic me-
tastasis, and 2 deaths were due to postoperative complica-
tions. This result was acceptable and comparable to the
results of standard lobectomy because pneumonectomy was
contraindicated in 1 patient.
Anastomotic complications are serious problems after
bronchoplastic procedures. Anastomotic fistula or dehis-
cence in the early postoperative period and late anastomotic
stenosis are 2 major anastomotic complications. As for earlyTABLE 6. Characteristics of limited group
No. Sex Age Resected lung Histology T N M Complication Recurrence Prognosis Cause of death
1 M 56 Left S415 Carcinoid 1 0 0 No No 127 mo, alive
2 M 61 Left S11213 SQ 1 1 0 No No 86 mo, alive
3 M 75 Left S11213 SQ 1 0 0 No No 107 mo, alive
4 M 78 Right S6 SQ 1 1 0 No RUL 35 mo, dead Other cause
5 M 72 Left S6 SQ 1 0 0 Prolonged air leak No 60 mo, alive
6 M 72 Left S11213 SQ 1 0 0 No No 41 mo, alive
7 M 71 Right ML S6 SQ 2 2 0 No No 23 mo, alive
8 F 28 Right ML S6 Carcinoid 1 0 0 No No 13 mo, alive
ML, Middle lobe; SQ, squamous cell carcinoma; RUL, right upper lobe.ovember 2008
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TSfistula or dehiscence, we recommend urgent surgical inter-
vention before fistula progresses to empyema. In fact, all 4
patients with anastomotic fistula were successfully treated
by surgical intervention. Late stenosis is another serious
problem because this condition can cause repetitive obstruc-
tive pneumonia, which interferes with the patient’s quality of
life.
Re-anastomosis is an option if the patient’s condition is
not poor. However, for patients with impaired pulmonary
function, surgical intervention is sometimes difficult and
stent insertion, laser coagulation, or tracheostomy is a possi-
ble palliative treatment to control bronchial secretion. In our
series, 6 of 7 patients with anastomotic complications were
successfully managed; therefore, aggressive surgical correc-
tion is worthwhile for postoperative anastomotic problems.
Another concern for bronchoplastic procedures is the
potentially increased incidence of local recurrence. The local
recurrence rate is reported to be 4.5% to 22%.1,5,8,11 This var-
iation is partly because there are differences in the definition
of local recurrence. If local recurrence is defined as relapse at
the anastomotic site or within the ipsilateral thorax, the local
recurrence rate is 7.9% in our series, and together with medi-
astinal recurrence, the local recurrence rate is 12.9%, which is
comparable to previously reported rates.1,5,8,11
With regard to long-term survival in our series, only nodal
status was identified by multivariate analysis as a significant
prognostic factor in overall survival and disease-free sur-
vival. The relationship between long-term survival and nodal
status has been reported.5,8,11,12 Van Schil and colleagues11
reported a significant difference in survival between patients
with N0 and N1 or N2 but not N1 and N2 disease. Neverthe-
less, others concluded that 5-year survival in patients with
N2 disease is close to 0%.5,8,12 In our series, overall 5-year
survival in patients with N0, N1, and N2 is 72%, 48%, and
32%, respectively, which is comparable to the results of con-
ventional lung resection for primary lung cancer.13 In other
words, the long-term results of sleeve lung resection and
conventional lung resection are comparable if the tumor
and involved lymph node are properly resected. Sleeve lo-
bectomy can thus be of the preferred procedure not only in
patients with N0 disease but also in patients with N1 or N2
disease.
Our greatest concern is whether avoidance of pneumonec-
tomy or lobectomy oncologically justifies aggressive appli-
cation of sleeve lung resection. Okada and colleagues6,10
reported the surgical results of extended sleeve lobectomy
and sleeve segmentectomy and concluded that these 2 types
of atypical bronchoplastic procedures are feasible without
anastomotic complications or local recurrence, and with
favorable long-term survival. In our series, extended sleeve
lobectomy and standard sleeve lobectomy were associated
with comparable long-term survival in multivariate analysis
and there was no local recurrence even in patients with N2
disease. We now prefer extended sleeve lobectomy to pneu-The Journal of Thoramonectomy because it preserves lung parenchyma that
improves quality of life and reduces late cardiopulmonary
insufficiency. It is the preferred procedure if the tumor and
involved lymph node can be resected. As for segmentec-
tomy, the Lung Cancer Study Group concluded that lobec-
tomy must be the surgical procedure of choice even for
patients with early lung cancer because higher locoregional
recurrence and death rate are associated with limited resec-
tion.14 This report considered segmentectomy and wedge
resection as a limited resection; therefore, its assessment of
segmentectomy is somewhat confused. In fact, several
authors report that segmentectomy can be an alterative to
lobectomy for treatment of early small lung cancer if patients
are carefully selected.15-17 In our series, no patient in our
limited group died as a result of recurrence and only 1 patient
experienced local recurrence in another lobe, which was suc-
cessfully resected. Also, no patient died as a result of a lung
cancer recurrence. Thus, sleeve segmentectomy is feasible
for carefully selected patients with early central tumor. A
small tumor at the segmental bronchus without nodal
involvement can be a good candidate for treatment by sleeve
segmentectomy.
Conclusions
Sleeve lung resection can achieve local tumor control and
long-term survival with low mortality and few anastomotic
complications. Nodal status significantly affects long-term
survival. Limited and extended resections are also feasible
with local and long-term results comparable to those of stan-
dard sleeve lobectomy.
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